NORML

SEPTEMBER 20, 2019

We also spoke with her attorneys, who explained why they believed the DEA broke the law by holding up long-promised medical marijuana research licenses. It’s been nearly three years since the DEA announced its revolutionary cultivator program. The only problem is, the program doesn’t actually exist.

DEA 230

DEA Research and Development Clinical Trials Patients 230

Veriheal

DECEMBER 30, 2020

If you answered yes to these two questions, then the DEA might have the job for you. The DEA is seeking a contractor that has the ability to destroy illegal drugs without leaving detectable levels behind. .” What about the option of donating the confiscated cannabis to a veteran program to be utilized in making RSO?

DEA 52

DEA Pharmaceutical Packaging Business 52

Cannabis Law Report

APRIL 8, 2022

Later that year, Doblin sued the DEA for the first time. MAPS continued to publish Bulletin articles about MDMA research , requests for donations , and discontinuing animal studies. submitted his first DEA application to manufacture marijuana for use in medical research. MAPS Founder Rick Doblin, Ph.D., Lyle Craker, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

MAY 25, 2022

DEA gave financial and technical assistance to the FDLE for cannabis control, but no money went to the spraying of paraquat. FDLE states that it is their plan to keep controlling cannabis with or without the DEA’s assistance.

DEA 40

DEA Law Environment Marijuana 40

Cannabis Law Report

APRIL 21, 2022

MDMA is a promising psychedelic compound, currently placed by the Drug Enforcement Administration (DEA) in Schedule I of the Controlled Substances Act, that has been produced for legal research in small batches by certified laboratories. ABOUT MAPS PUBLIC BENEFIT CORPORATION (MAPS PBC) .

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52